Our findings strongly advocate for somatic and germline testing including BRCA1/2 in the evaluation of prostate cancer, especially in cases of metastasis at presentation and a Gleason grade group 5 disease, even if their PSA is lower than 100 ng/mL. This evidence concerns the gene BRCA1 and Familial prostate cancer.